BeOne Medicines Ltd.
ONCBeOne Medicines, formerly known as BeiGene, Ltd. is a multinational oncology company. It specializes in the development of drugs for cancer treatment. Founded in 2010 by chief executive officer John V. Oyler and Xiaodong Wang, the company is headquartered in Cambridge, Massachusetts and has locations on six continents, in over 45 countries. BeOne has a large presence in the Chinese market.
Drugs in Pipeline
12
Phase 3 Programs
9
Upcoming Catalysts
3
Next Catalyst
Aug 5, 2026
6wMarket Overview
Stock performance and key metrics
3 upcoming, 2 past
BGB-16673
B-cell Malignancy
Tislelizumab
Advanced Malignancies
BGB-43395
HR+/HER2- Breast Cancer
Tacrolimus
Primary Membranous Nephropathy
Subcutaneous Tislelizumab
Metastatic Gastric Adenocarcinoma
Pirtobrutinib
Chronic Lymphocytic Leukemia
Venetoclax
CLL
Bendamustine
CLL
Sonrotoclax
Mantle Cell Lymphoma
Dexamethasone
Relapsed/Refractory Multiple Myeloma
Zanubrutinib
Chronic Lymphocytic Leukemia
Capecitabine
Advanced Unresectable Gastric Adenocarcinoma
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
BGB-16673 | Phase 3 | B-cell Malignancy | - | - |
Tislelizumab | Phase 3 | Advanced Malignancies | - | - |
BGB-43395 | Phase 3 | HR+/HER2- Breast Cancer | - | - |
Tacrolimus | Phase 3 | Primary Membranous Nephropathy | - | - |
Subcutaneous Tislelizumab | Phase 3 | Metastatic Gastric Adenocarcinoma | - | - |
Pirtobrutinib | Phase 3 | Chronic Lymphocytic Leukemia | - | - |
Venetoclax | Phase 3 | CLL | - | - |
Bendamustine | Phase 3 | CLL | - | - |
Sonrotoclax | Phase 3 | Mantle Cell Lymphoma | - | - |
Dexamethasone | Phase 2 | Relapsed/Refractory Multiple Myeloma | - | - |
Zanubrutinib | Phase 2 | Chronic Lymphocytic Leukemia | - | - |
Capecitabine | Phase 2 | Advanced Unresectable Gastric Adenocarcinoma | - | - |